TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01129648

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered daily for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administered daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Adminstered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Adminstered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Adminstered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Adminstered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Adminstered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Adminstered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Adminstered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Adminstered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4208
Description: Adminstered daily for 21 days
Study: NCT03100032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVD-001
Description: At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with NVD-001.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with autologous locally cancellous bone (laminectomy)
Study: NCT03342105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cettum
Description: The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Moxibustion will be provided at 11 standard acupuncture points: EX-HN3, and both EX-HN8, LI20, LI4, GB2, ST36. A specifically designed device, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea), will be used to treat patients in this group. The expected total time of each treatment session will be 15 min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Acupuncture will be provided at same points in the Cettum group. Sterile stainless steel disposable acupuncture needles (0.25X30mm, DongBang Acupuncture Inc, Korea) will be used to treat patients in this group. The needles will be kept in place for 15 min.
Study: NCT00528658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400mg tid
Study: NCT01430351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: Given PO
Study: NCT02929420

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xiao Yao pills
Description: Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
Study: NCT01430351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT00528658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400mg tid
Study: NCT01703806

Intervention type: PROCEDURE
Intervention: Early Surgery
Description: MItral valve surgery

Intervention type: PROCEDURE
Intervention: Watchful Observation
Description: Watchful observation
Study: NCT00528658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol Placebo
Description: equivalent to 1g qid
Study: NCT02986698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: in utero hematopoietic stem cell transplantation
Description: This is a phase 1 safety study to demonstrate it is safe for both the mother and fetus to perform In utero hematopoietic stem cell transplantation of maternal derived stem cells at the time of intrauterine transplantation of red blood cells to treat fetuses affected with alpha-thalassemia major.
Study: NCT00528658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen placebo
Description: Equivalent to 400mg tid
Study: NCT01516554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Description: 40 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice daily
Study: NCT04047875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethisterone 10mg/day
Description: NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
Study: NCT02495441

Intervention type: OTHER
Intervention: Use of Rapid Immunoassay Tests for the Detection of PROM
Description: After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.~The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.~Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®.
Study: NCT01554150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Method of Levels Cognitive Therapy
Description: In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
Study: NCT01958320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacologic treatment of the PDA
Description: Following randomization, infants will be treated with medications used to produce PDA closure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no pharmacologic treatment of the PDA
Description: Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
Study: NCT01633632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: 30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
Study: NCT01958320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
Study: NCT01443988

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent
Description: Implantation of two iStent devices

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost
Description: Travoprost drops
Study: NCT00235898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoFactor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study: NCT02275871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: High risk screening MRI will be performed as part of the patient's routine care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CESM
Description: After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
Study: NCT01709890

Intervention type: DEVICE
Intervention: YO2(R) catheter
Study: NCT04217876

Intervention type: DIAGNOSTIC_TEST
Intervention: post-processing analysis of cardiac imaging (strain echocardiography)
Description: A dedicated software package for two-dimensional speckle tracking strain analysis (XStrain™, Esaote, Florence, Italy) was used to quantify both ENDO and EPI strains. Our echocardiographic imaging acquisition protocol for 2DSTE consisted in the acquisition of three consecutive cardiac cycles from non-foreshortened apical views (4, 2, and 3 chambers) obtained during breath hold. Frame-by- frame displacement of ENDO and EPI points was automatically evaluated, generating strain curves for each segment.~The tracking quality was verified for each segment, and subsequent manual adjustments were performed, when required. All data were analyzed with the aid of Fourier techniques, which ensure greater accuracy using the periodicity of the heart motion.
Study: NCT02193568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (light sedation)
Description: If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm II (intubated general anesthesia)
Description: Receive intubated general anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm II (intubated general anesthesia)
Description: Undergo craniotomy
Study: NCT01633632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: 30 minutes of instruction in Hatha yoga will be provided for 8 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: 8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: 8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
Study: NCT01879462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
Study: NCT02193568

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm II (intubated general anesthesia)
Description: Undergo craniotomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm II (intubated general anesthesia)
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm II (intubated general anesthesia)
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (light sedation)
Description: Undergo craniotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm I (light sedation)
Description: Undergo craniotomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm I (light sedation)
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm I (light sedation)
Description: Ancillary studies
Study: NCT03888105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion
Study: NCT04123795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Certolizumab pegol
Description: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use
Study: NCT04704921

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ABBV-RGX-314
Description: AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ABBV-RGX-314
Description: AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (LUCENTIS®)
Description: 0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
Study: NCT01743807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNKG168
Description: GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.~Dose Level 0: 0.15 mg/kg Dose Level 1: 0.25 mg/kg Dose Level 2: 0.75 mg/kg Dose Level 3: 1.5 mg/kg~The starting dose level for the trial will be 0.25 mg/kg. If that dose level proves to be intolerable, the dose will be reduced to 0.15 mg/kg (dose level 0). If the 0.15 mg/kg dose level is intolerable due to DLTs, TACL, the Principal Investigator, and Medical Monitor will then decide the best course of action for subsequent administration of GNKG168.
Study: NCT00855920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept
Description: Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept
Description: Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
Study: NCT01574274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SC-PEG
Description: 11 doses Intravenously over one hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oncaspar
Description: 16 doses Intravenously over one hour
Study: NCT03884998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03781414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Comparison with standard of care immunosuppression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Comparison with standard of care immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus - MMF - corticosteroids
Description: Standard of care immunosuppresive regimen
Study: NCT02986984

Intervention type: OTHER
Intervention: There is no intervention
Description: There are no interventions

Intervention type: OTHER
Intervention: There is no intervention
Description: There are no interventions
Study: NCT03662776

Intervention type: BEHAVIORAL
Intervention: BASC-3 survey
Description: A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.

Intervention type: BEHAVIORAL
Intervention: BASC-3 survey
Description: A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.

Intervention type: BEHAVIORAL
Intervention: PROMIS survey
Description: A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.

Intervention type: BEHAVIORAL
Intervention: PROMIS survey
Description: A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
Study: NCT02098265

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electric Stimulation (FES)
Description: FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Assessments
Description: These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
Study: NCT01879462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.